

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε Conditional Bispecific Redirected Activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors

TPS2684

Gary Richardson,¹ Ganessan Kichenadasse,² Nicholas Zorko,³ Wen Wee Ma,⁴ Hui-Zi Chen,⁵ David Starks,⁶ Sarah Sutherland,⁷ Sujana Kamasani,⁸ Antari Khot,⁸ Xin Ma,⁸ William L. Trepicchio,⁸ Yefei Zhang,⁸ Elizabeth Ahern⁹

¹Cabrini Research, Melbourne, Australia; ²Southern Oncology Clinical Research Unit Pty Ltd, Adelaide, Australia; ³University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA; ⁴Cleveland Clinic, Cleveland, OH, USA; ⁵Medical College of Wisconsin, Milwaukee, WI, USA; ⁶Avera Cancer Institute, Sioux Falls, SD, USA; ⁷Chris O'Brien Lifehouse, Sydney, Australia; ⁸Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA; ⁹Monash Health, Melbourne, Australia

